title: Antiangiogenic effect of silicate nanoparticle on retinal neovascularization induced by vascular endothelial growth factor.
abstract: Angiogenesis-related blindness indicates the spectrum of retinal diseases that are caused by pathological angiogenesis, resulting in catastrophic vision loss. We aimed to demonstrate the antiangiogenic effect of silicate nanoparticles (SiNPs) on the retinal neovascularization. No direct toxicity of SiNPs was observed on retinal neuronal or endothelial cells, nor on the retinal tissue. Furthermore, intravitreal injection of SiNPs effectively reduced anomalous retinal angiogenesis in oxygen-induced retinopathy mice. SiNPs also effectively inhibited in vitro vascular endothelial growth factor (VEGF)-induced angiogenesis. Via suppression of VEGF receptor-2 phosphorylation induced by VEGF, SiNPs blocked ERK 1/2 activation. SiNPs could be an inhibitor of the potency and safety of retinal neovascularization that is mediated by VEGF and utilized in the treatment of angiogenesis-related blindness.
  
  
  BACKGROUND
  In this important preclinical study, silicate NP-s are studied to address retinal neovascularization, an important pathomechanism of different retinal diseases that could lead to catastrophic vision loss. The authors conclude that SiNP-s could be utilized as inhibitors of retinal neovascularization mediated by VEGF and propose future applications in the treatment of angiogenesis-related blindness.
authors.affiliation: Fight Against Angiogenesis-Related Blindness Laboratory, Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Republic of Korea.
authors.forename: Dong Hyun
authors.initials: DH
authors.lastname: Jo
authors.forename: Jin Hyoung
authors.initials: JH
authors.lastname: Kim
authors.forename: Young Suk
authors.initials: YS
authors.lastname: Yu
authors.forename: Tae Geol
authors.initials: TG
authors.lastname: Lee
authors.forename: Jeong Hun
authors.initials: JH
authors.lastname: Kim
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000737:chemistry; D000818:Animals; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D042783:Endothelial Cells / Q000166:cytology; D006801:Humans; D058449:Intravitreal Injections; D020935:MAP Kinase Signaling System / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry; D010100:Oxygen / Q000494:pharmacology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D015861:Retinal Neovascularization / Q000139:chemically induced / Q000188:drug therapy; D055351:Retinal Neurons / Q000187:drug effects; D017640:Silicates / Q000008:administration & dosage / Q000737:chemistry; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology*
chemical_list: D020533:Angiogenesis Inhibitors; D017640:Silicates; D042461:Vascular Endothelial Growth Factor A; D040262:Receptors, Vascular Endothelial Growth Factor; D010100:Oxygen